Marzo-Ortega H, McGonagle D, Emery P
Rheumatology and Rehabilitation Research Unit, University of Leeds, UK.
Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S175-7.
Biologic blockade of tumour necrosis factor alpha is an exciting new development in the treatment of the spondyloarthropathies (SpA). Recent reports suggest that both infliximab and etanercept are potent suppressors of inflammation in SpA and this has been confirmed by studies showing suppression of inflammatory indices as well as complete regression or improvement in the inflammatory lesions as shown by magnetic resonance imaging (MRI). Whilst limited follow up data have been reported in the case of infliximab there are no data on how patients on etanercept fare after a years' treatment.
肿瘤坏死因子α的生物阻断疗法是脊柱关节病（SpA）治疗领域一项令人振奋的新进展。近期报告表明，英夫利昔单抗和依那西普都是SpA炎症的强效抑制剂，这一点已得到研究证实，这些研究显示炎症指标受到抑制，同时磁共振成像（MRI）显示炎症病灶完全消退或改善。虽然英夫利昔单抗方面报告的随访数据有限，但尚无依那西普治疗一年后患者情况的数据。
